Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ibex, Oncotherapeutics Inc. deal

IBT will acquire Oncotherapeutics, which holds exclusive rights to protease kallikrein cancer

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE